IMPAKT 2013: Sponsors
Tel: +41 61 688 11 11
Fax: +41 61 691 93 91
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, infectious diseases, inflammation, metabolism and neuroscience. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Roche’s personalised healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2012 Roche had over 82,000 employees worldwide and invested over 8 billion Swiss francs in R&D. The Group posted sales of 45.5 billion Swiss francs. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.
All trademarks used or mentioned in this release are protected by law.
180 Park Avenue
Florham Park, NJ 07932
United States of America
Tel: +1 862 778 8300
Fax: +1 973 781 3014
Novartis Oncology discovers and develops innovative therapies, including Glivec® (imatinib), Tasigna® (nilotinib), Afinitor® (everolimus), Zometa® (zoledronic acid), Femara® (letrozole), Sandostatin® LAR® (octreotide acetate for injectable suspension) and Exjade® (deferasirox). Novartis has one of the broadest and most comprehensive oncology pipelines in the industry.
New York City, New York 10017
United States of America
Tel: +1 212-733-2323
Pfizer Oncology is committed to the discovery, investigation and development of innovative treatment options to improve the outlook for cancer patients worldwide. Our strong pipeline of biologics and small molecules is studied with precise focus on identifying and translating the best scientific breakthroughs into clinical application for patients across a wide range of cancers.
10 rue d'Arcueil
Tel: +33 145 60 11 78
Abbvie is a global biopharmaceutical company focused on developing advanced therapies that address some of the world’s most complex and serious diseases. Abbvie is a leader in addressing these challenges, with an expanded focus on biologics and targeted medicine. we use our knowledge and expertise to develop therapies that address difficult conditions affecting significant patient populations. our priority is our patients and helping them lead healthier lives.
Amgen (Europe) GmbH
Tel: +41 41 3690 300
Fax: +41 41 3690 400
Amgen discovers, develops, manufactures, and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realise the new science’s promise by bringing safe, effective medicines from lab to manufacturing plant to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, bone disease, and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people’s lives. For more information, visit www.amgen.com and follow us on www.twitter.com/amgen.
Breakthrough Breast Cancer
Our mission is to save lives through improvements in breast cancer, prevention, diagnosis and treatment. Under the overarching goal of a personalised approach to medicine, the strategy is defined by four priority areas:
- By finding the causes we will know how to prevent the disease
- By promoting early detection more women will recognise the signs and symptoms of breast cancer
- By finding ways to make diagnosis of the disease more accurate, more women will receive precise treatments
- By discovering new and better treatments and improving health services, women will receive effective guaranteed treatments and care
Tel: +32 2 7229797
Fax: +32 2 7229790
Helping to Make Quality Healthcare Available to All
Whether the cause be an ageing population, changing lifestyle patterns or poor economic outlook, health care systems around the world are struggling to cope with the reality of increasing cost containment pressures. But this challenge is not without a solution – generic pharmaceuticals provide significant savings for both patients and healthcare systems alike. In this way, generics also free up resources for the funding of costlier novel therapies, benefiting patients and incentivising investment in new, innovative medicines that target unmet medical needs. At Sandoz, we are steadfast in our commitment to continually increase patient access to high-quality, affordable medicines.
Premium Educational Grants
Science Park 406
1098 XH Amsterdam
Tel: +31 20 462 1555
Fax: +31 20 462 1505
Agendia is a leading global commercial molecular diagnostic company that develops and markets genomic-based diagnostic products that improve the quality of life for cancer patients and simplifies complex treatment decisions for their physicians. Agendia’s Symphony™ suite of breast cancer products is based on the analysis of hundreds of genes in a patient’s breast and provides unprecedented biological insight to address complex treatment decisions. Symphony™ includes MammaPrint® the first and only FDA-cleared IVDMIA breast cancer recurrence assay, as well as BluePrint®¬¬, a molecular subtyping assay, TargetPrint®, an ER/PR/HER2 expression assay, and TheraPrint®, a therapy selection assay. MammaPrint is since early 2012 also available in FFPE tissue.
Celgene Corporation is an integrated global biopharmaceutical company committed to improving the lives of patients worldwide. Our mission is to build a major global biopharmaceutical corporation while focusing on the discovery, the development, and the commercialisation of products for the treatment of cancer and other severe, immune, inflammatory conditions.
Outside of the United States, Celgene’s International HQ is based in Boudry, Switzerland and the company operates throughout Europe and Asia Pacific.
Genomic Health International Sàrl
Quai du Seujet 10
Tel: 001 650 569 2080
Toll free: 00 800 662 68973 (Austria, France, Germany, Italy, Switzerland and UK)
Genomic Health, Inc. is a global healthcare company that provides actionable genomic information to personalise cancer treatment decisions. The company's lead product, the Oncotype DX® breast cancer test, has been shown to predict the likelihood of chemotherapy benefit as well as recurrence in invasive breast cancer and has been shown to predict the likelihood of recurrence in DCIS. More than 10,000 physicians in over 70 countries had ordered approximately 335,000 Oncotype DX tests. Genomic Health has a robust pipeline focused on developing tests to optimise additional treatment decisions in breast cancer. To learn more about Oncotype DX tests, visit: www.OncotypeDX.com
Leica Biosystems GmbH
Heidelberger Straße 17-19
Tel: +49 6224 143 0
Fax: +49 6224 143 268
Leica Biosystems is a global leader in laboratory workflow solutions for anatomic pathology, striving to advance cancer diagnostics to improve patients’ lives. Leica Biosystems provides a comprehensive product range, from sample preparation, staining and imaging to reporting.
Leica Biosystems’ integration of Aperio ePathology Solutions, enables greater access for Pathologists through market-leading whole-slide scanners, NETWORK solutions for remote, e-slide viewing and PRECISION solutions, providing quantitative image analysis to improve productivity and consistency.
Leica Biosystems is represented in over 100 countries. It has manufacturing facilities in 7 countries, sales and service organisations in 19 countries, and an international network of dealers.
9 Grange Gardens
SM7 3RF, Surrey
Tel: +44 787 523 8657
Fax: +1 206 378 6288
NanoString Technologies is a provider of life science tools for translational research and developer of molecular diagnostics. The company’s nCounter® Analysis System is the first and only technology platform to deliver highly multiplexed, direct profiling of individual molecules in a single reaction without amplification. The nCounter Analysis System offers a cost-effective way to easily profile hundreds of gene transcripts, copy number variations, or miRNAs simultaneously with high sensitivity and precision. The company’s technology enables a wide variety of basic research and translational medicine applications, including biomarker discovery and validation. NanoString is also developing the technology for use in molecular diagnostics.
Sividon Diagnostics GmbH
Sividon Diagnostics is a management buyout from Siemens Healthcare Diagnostics' former research site in Cologne, Germany. Sividon's team includes experienced scientists and managers with decades of experience in the diagnostics industry and in academia. Sividon's products have been designed to improve the quality of therapy selection in oncology by supplying personalised and evidence-based molecular diagnostics tools. Sividon’s first product is the CE-marked EndoPredict. Sividon has shown in independent clinical studies that EndoPredict is able to select patients with primary breast cancer that have a more than 95% likelihood of 10 years of metastasis-free survival under endocrine therapy and in absence of chemotherapy. EndoPredict therefore provides a basis to improve patient care and spare women with breast cancer from unnecessary chemotherap.
Susan G. Komen for the Cure
Nancy G. Brinker promised her dying sister, Susan G. Komen, she would do everything in her power to end breast cancer forever. In 1982, that promise became Susan G. Komen for the Cure, which is now the world’s largest breast cancer organisation and the largest source of nonprofit funds dedicated to the fight against breast cancer with nearly $1.5 billion invested to date. For more information about Susan G. Komen for the Cure, breast health or breast cancer, visit www.komen.org.
Standard Educational Grants
Astellas Pharma Europe Ltd
2000 Hillswood Drive
Surrey KT16 0RS
Tel: +44 203 379 8700
Fax: +44 203 379 8260
Astellas is already a proven player in the fields of Transplantation, Urology, Dermatology, Anti-Infectives and Pain Management. We are now bringing this expertise to bear in the field of oncology. Already we have no fewer than 12 separate therapies under clinical development. Through these programmes, we aim to fulfil not just our potential, but our promise to change tomorrow for patients suffering with conditions such as prostate cancer, other solid tumours such as pancreatic and breast cancer, advanced renal cell carcinoma and haematological malignancies.
Eisai is one of the world's leading research and development (R&D) based pharmaceutical companies and we define our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call human health care (hhc).
Eisai concentrates its R&D activities in three key areas:
- Neuroscience, including: Alzheimer's disease, epilepsy, pain and weight los
- Oncology including: anticancer therapies; tumour regression, tumour suppression, antibodies, etc
- Vascular/Immunological reaction including: thrombocytopenia, rheumatoid arthritis, psoriasis, and inflammatory bowel disease
With operations in the U.S., Asia, Europe and its domestic home market of Japan, Eisai employs more than 11,000 people worldwide. From its Europe based Knowledge Centre in Hatfield, UK, Eisai has recently expanded business operations to include the expanded territory of Europe, the Middle East, Africa and Russia (EMEA). Eisai EMEA undertakes sales and marketing operations in over 20 markets, including the United Kingdom, France, Germany, Italy, Spain, Switzerland, Sweden, Ireland, Austria, Denmark, Finland, Norway, Portugal, Iceland, Czech Republic, Slovakia, the Netherlands, Belgium, Luxembourg, the Middle East and Russia. For further information please visit: www.eisai.com